NEPENTHE - Next Generation Personalized Neuroblastoma Therapy

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

9 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This is a clinical trial for patients with neuroblastoma that has returned (relapsed) or has not responded to standard treatment. The patients will have a biopsy of their tumor that will be tested for genetic changes and then matched to available drugs. If the results from the testing show molecular features in the tumor that allow for study treatment, patients will be invited for further testing to see if they are eligible for new treatments. Experimental therapies are all taken orally and may consist of one drug or a combination of drugs.

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at mosse [at] chop.edu.

Eligibility & Criteria

IRB #:
14-011071
Official Title:
NEPENTHE: Next Generation Personalized Neuroblastoma Therapy
Study Phase:
Phase I
Phase II
Eligible Age Range:
Any
Gender:
All
Study Categories:
Leader
Yael P. Mossé

Yael P. Mossé, MD